Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived mononuclear cell
- Development stage
- Phase 3
- Lead developer
- Vinmec Research Institute of Stem Cell and Gene Technology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal, Intramuscular, Intramyocardial, Intravitreal, Intra-arterial, Intravenous
01
Overview
Autologous bone marrow-derived mononuclear cells (BMMNCs) represent a heterogeneous cell population harvested from a patient's own bone marrow, typically via iliac crest aspiration. This mixture includes hematopoietic stem cells, mesenchymal stem cells, endothelial progenitor cells, and various mature leukocytes. The therapeutic rationale relies on the paracrine effect, where the transplanted cells secrete a cocktail of neurotrophic factors (such as NGF and GDNF), angiogenic factors (like VEGF and FGF2), and anti-inflammatory cytokines to modulate the local microenvironment, reduce apoptosis, and stimulate endogenous repair. Because the cells are autologous, the risk of immune rejection is minimized. BMMNCs are currently being investigated across a broad spectrum of indications, particularly neurological disorders like cerebral palsy, stroke, and spinal cord injury, as well as cardiovascular and ischemic limb diseases.
- Other names
- autologous bone marrow mononuclear cellsBMMNCBM-MNCBM-MNSCsautologous bone marrow stem cells
Beyond the preview
Go deeper on autologous bone marrow-derived mononuclear cell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived mononuclear cell.